Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
- 28 February 1999
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 35 (2), 208-213
- https://doi.org/10.1016/s0959-8049(98)00392-x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- 0-75. Letrozole as primary medical therapy for locally advanced breast cancerThe Breast, 1997
- A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinomaCancer, 1997
- Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot studyAnnals of Oncology, 1996
- An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cellsInternational Journal of Cancer, 1995
- The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Aromatase activity, serum oestradiol and their correlation with demographic indicesThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissuesInternational Journal of Cancer, 1991
- The New Aromatase Inhibitor CGS-16949A SuppressesAldosterone and Cortisol Production by Human Adrenal Cellsin vitroJournal of Clinical Endocrinology & Metabolism, 1989
- Assessment of response to therapy in advanced breast cancerEuropean Journal of Cancer (1965), 1977